Breast cancer diagnosis and staging in Chile: A non-randomized survey-based study to assess frequency and delays

Estudios originales

Published on 14 de octubre de 2024 | http://doi.org/10.5867/medwave.2024.09.2801

Breast cancer diagnosis and staging in Chile: A non-randomized survey-based study to assess frequency and delays

Diagnostic tests requested according to staging and health prognosis [].

	Public		Private		Total
	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)
Stage I and II
Biopsy	108	100%(-)	48	100%(-)	156	100%(-)
Blood test	87	80.6%(73.2% to 88.0%)	39	81.3%(45.6% to 69.1%)	126	80.8%(74.4% to 86.5%)
CTc	80	74.1%(65.7% to 82.4%)	39	81.3%(45.6% to 69.1%)	119	76.3%(69.2% to 82.7%)
Abdominal and pelvic US	55	50.9%(41.7% to 60.2%)	27	56.3%(41.7% to 70.8%)	82	52.6%(44.9% to 60.3%)
Abdominal and pelvic CT	61	56.5%(47.2% to 65.7%)	32	66.7%(54.2% to 79.2%)	93	59.6%(51.92% to 67.3%)
Bone scintigram	73	67.6%(47.2% to 65.7%)	30	62.5%(47.9% to 77.1%)	103	66.0%(58.3% to 73.1%)
Chest X-ray	56	51.9%(42.6% to 61.1%)	27	56.3%(41.7% to 70.8%)	83	53.2%(45.5% to 60.9%)
PET	19	17.6%(11.1% to 25.0%)	11	22.9%(12.5% to 35.4%)	30	19.2%(13.5% to 25.6%)
Stages III and IV
Biopsy	63	98.4%(95.3% to 100%)	24	100.0%(-)	87	98.9%(96.6% to 100%)
Blood test	51	79.7%(68.8% to 89.1%)	24	100.0%(-)	75	85.2%(77.3% to 92.1%)
CTc	55	85.9%(76.6% to 93.8%)	23	95.8%(87.5% to 100%)	78	88.6%(81.8% to 94.3%)
Abdominal and pelvic US	39	60.9%(48.4% to 73.4%)	18	75.0%(58.3% to 91.7%)	57	64.8%(54.6% to 75.0%)
Abdominal and pelvic CT	41	64.1%(51.6% to 75.0%)	21	87.5%(75.0% to 100%)	62	70.5%(61.4% to 79.6%)
Bone scintigram	52	81.3%(71.9% to 90.6%)	24	100.0%(-)	76	86.4%(78.4% to 93.2%)
Chest X-ray	39	60.9%(48.4% to 73.4%)	17	70.8%(50.0% to 87.5%)	56	63.6%(53.4% to 73.9%)
PET	19	29.7%(18.5% to 40.6%)	8	33.3%(16.7% to 54.2%)	27	30.7%(21.6% to 40.9%)

CI, confidence interval. CT, computed axial tomography. HER2, estrogen receptor. Ki67, progesterone receptor. PET, positron emission tomography. US, ultrasound.

Notes: Information obtained from participants who live or have lived with breast cancer in the Chilean healthcare system. Blood tests to evaluate tumor biomarkers (HER2, Ki67) and PET.

Source: Prepared bu the authors.